Bonsai Biotherapeutics is a startup based in Sweden, 1 tracked investor.
Based in Sweden, Bonsai Biotherapeutics is a startup. Brouky records 1 investor associated with the company.
Bonsai Biotherapeutics is a Sweden-based biotech company developing protein-based therapeutics that restore immune tolerance to self-proteins in autoimmune diseases such as myasthenia gravis (MG) and ANCA-associated vasculitis. Its lead candidate, TOL2 for MG, is composed of modified versions of the targeted proteins and is expected to enter a placebo-controlled clinical trial in 2026.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.